CA2445612A1 - Methods and compositions for treating mammalian nerve tissue injuries - Google Patents
Methods and compositions for treating mammalian nerve tissue injuries Download PDFInfo
- Publication number
- CA2445612A1 CA2445612A1 CA002445612A CA2445612A CA2445612A1 CA 2445612 A1 CA2445612 A1 CA 2445612A1 CA 002445612 A CA002445612 A CA 002445612A CA 2445612 A CA2445612 A CA 2445612A CA 2445612 A1 CA2445612 A1 CA 2445612A1
- Authority
- CA
- Canada
- Prior art keywords
- glycol
- composition
- injury
- fusion agent
- nerve tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
To achieve, an in vivo repair of injured mammalian nerve tissue, an effectiv e amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injur y. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusi on agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tiss ue injury.
Claims (21)
1. Pharmaceutical composition for use in treating an injury to nerve tissue of a mammalian patient, the composition comprising an effective amount of a biomembrane fusion agent formulated for delivery via the patient's vascular system to the site of the injured nerve tissue; and optionally a pharmaceutical carrier.
2. Use of a biomembrane fusion agent for the preparation of a pharmaceutical composition for treatment of an injury to nerve tissue of a mammalian patient.
3. Method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a biomembrane fusion agent and optionally a pharmaceutical carrier to the patient so that biomembrane fusion agent is delivered via the patient's vascular system to the site of the injured nerve tissue.
4. The composition, use or method of any of the preceding claims wherein said biomembrane fusion agent comprises at least one hydrophilic polymer.
5. The composition, use or method of claim 4 wherein said hydrophilic polymer comprises at least one polyalkylene glycol.
6. The composition, use or method of claim 5 wherein said polyalkylene glycol is taken from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers thereof.
7. The composition, use or method of claim 5 wherein said polyalkylene glycol comprises polyethylene glycol.
8. The composition, use or method of claim 4 wherein said hydrophilic polymer comprises a dextran.
9. The composition, use or method of claim 8 wherein said hydrophilic polymer has a molecular weight of about 400 daltons to about 3500 daltons.
10. The composition, use or method of any of claims 1 to 3 wherein the biomembrane fusion agent comprises an amphipathic polymer.
11. The composition, use or method of claim 10 wherein said amphipathic polymer comprises a block copolymer.
12. The composition, use or method of claim 11 wherein said block copolymer is taken from the group consisting of polyalkylene glycol block copolymers, mixtures of polyalkylene glycol block copolymers, and mixtures of polyalkylene glycols and polyalkylene glycol block copolymers.
13. The composition, use or method of claim 11 wherein said block copolymer comprises at least one compound taken from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers thereof.
14. The composition, use or method of any of claims 10 to 13 wherein said amphipathic polymer is taken from the group consisting of polyethylene glycol/polypropylene glycol block copolymers, and mixtures of polyethylene glycol, polypropylene glycol, and polyethylene glycol/polypropylene glycol block copolymers.
15. The composition, use or method of claim 10 wherein said amphipathic polymer is taken from the group consisting of poloxamers and poloxamines.
16. The composition, use or method of any of the preceding claims wherein the injured nerve tissue is spinal cord tissue.
17. The composition, use or method of any of claims 1 to 15 wherein the injured nerve tissue is peripheral nerve tissue.
18. The composition, use or method any of the preceding claims wherein the injury is a mechanical injury, a biochemical injury and/or an ischemic injury.
19. The composition, use or method of claim 18 wherein the ischemic injury is a stroke and/or a head injury.
20. The pharmaceutical composition of any of claims 1 and 4 to 19 wherein said effective amount of said biomembrane fusion agent is effective for injecting said biomembrane fusion agent intraveneously, intramuscularly, subcutaneously, or intraperitoneally into the patient, or into or near the nerve sheath at the site of injury.
21. The method of any of claims 3 to 19 wherein administration of an effective amount of said biomembrane fusion agent is effected using a technique selected from the group consisting of intravascular, intramuscular, subcutaneous and intraperitoneal injection, or by injecting said biomembrane fusion agent into or near the nerve sheath at the site of injury.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2740056A CA2740056A1 (en) | 2001-04-24 | 2002-04-24 | Methods and compositions for treating mammalian nerve tissue injuries |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28620001P | 2001-04-24 | 2001-04-24 | |
US60/286,200 | 2001-04-24 | ||
PCT/US2002/013375 WO2002092107A1 (en) | 2001-04-24 | 2002-04-24 | Method and compositions for treating mammalian nerve tissue injuries |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2740056A Division CA2740056A1 (en) | 2001-04-24 | 2002-04-24 | Methods and compositions for treating mammalian nerve tissue injuries |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2445612A1 true CA2445612A1 (en) | 2002-11-21 |
CA2445612C CA2445612C (en) | 2011-10-25 |
Family
ID=23097525
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2445612A Expired - Fee Related CA2445612C (en) | 2001-04-24 | 2002-04-24 | Methods and compositions for treating mammalian nerve tissue injuries |
CA2740056A Abandoned CA2740056A1 (en) | 2001-04-24 | 2002-04-24 | Methods and compositions for treating mammalian nerve tissue injuries |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2740056A Abandoned CA2740056A1 (en) | 2001-04-24 | 2002-04-24 | Methods and compositions for treating mammalian nerve tissue injuries |
Country Status (9)
Country | Link |
---|---|
US (4) | US7837987B2 (en) |
EP (1) | EP1389121B1 (en) |
JP (2) | JP2004527573A (en) |
AT (1) | ATE546146T1 (en) |
AU (2) | AU2002314758B2 (en) |
CA (2) | CA2445612C (en) |
ES (1) | ES2382899T3 (en) |
NZ (2) | NZ529526A (en) |
WO (1) | WO2002092107A1 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7582680B1 (en) | 1998-11-12 | 2009-09-01 | Purdue Research Foundation | Methods and compositions for treating mammalian spinal cord injuries |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
CA2445612C (en) | 2001-04-24 | 2011-10-25 | Purdue Research Foundation | Methods and compositions for treating mammalian nerve tissue injuries |
US7147647B2 (en) | 2002-04-26 | 2006-12-12 | Medtronic, Inc. | Sintered titanium tube for the management of spinal cord injury |
JP4571776B2 (en) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | Lubricating oil composition |
ES2328640T3 (en) | 2003-04-18 | 2009-11-16 | Biogen Idec Ma Inc. | NEUBLASTIN CONJUGATED WITH A GLYCOSILATED POLYMER. |
CN101123978B (en) | 2004-08-19 | 2012-12-12 | 比奥根艾迪克Ma公司 | Neublastin variants |
PT1786454E (en) * | 2004-08-19 | 2010-08-18 | Biogen Idec Inc | Neublastin variants |
WO2006044738A2 (en) * | 2004-10-18 | 2006-04-27 | Maroon Biotech Corporation | Methods and compositions for treatment of free radical injury |
CN101084272B (en) * | 2004-12-21 | 2011-07-13 | 路博润有限公司 | Compositions |
US20070048731A1 (en) * | 2005-05-20 | 2007-03-01 | Neurosilicon | High throughput use-dependent assay based on stimulation of cells on a silicon surface |
CA2609196A1 (en) | 2005-05-31 | 2006-12-07 | Warsaw Orthopedic, Inc. | Compositions and methods for treating pain |
US20070017530A1 (en) * | 2005-06-10 | 2007-01-25 | Syed Naweed I | Detecting electrical activity and assessing agents for the ability to influence electrical activity |
US20060287660A1 (en) * | 2005-06-15 | 2006-12-21 | Syed Naweed I | Electrically Stimulating Nerve Regeneration |
US20060292549A1 (en) * | 2005-06-15 | 2006-12-28 | Neurosilicon | Psychotropic drug screening device based on long-term photoconductive stimulation of neurons |
JP4907908B2 (en) * | 2005-06-29 | 2012-04-04 | ルネサスエレクトロニクス株式会社 | Driving circuit and display device |
WO2007009235A1 (en) * | 2005-07-15 | 2007-01-25 | Neurosilicon (1145990 Alberta Ltd.) | Method and apparatus for guiding growth of neurons |
US20070213717A1 (en) * | 2006-02-14 | 2007-09-13 | Sdgi Holdings, Inc. | Biological fusion in the vertebral column |
US20070213718A1 (en) * | 2006-02-14 | 2007-09-13 | Sdgi Holdings, Inc. | Treatment of the vertebral column |
US20070227547A1 (en) * | 2006-02-14 | 2007-10-04 | Sdgi Holdings, Inc. | Treatment of the vertebral column |
US7520888B2 (en) * | 2006-02-14 | 2009-04-21 | Warsaw Orthopedic, Inc. | Treatment of the vertebral column |
TWI501774B (en) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | Treatments for neurological disorders |
EP1993590B1 (en) * | 2006-03-01 | 2013-12-25 | Biogen Idec MA Inc. | Compostions and methods for administering gdnf ligand family proteins |
US8840933B2 (en) | 2006-05-03 | 2014-09-23 | Warsaw Orthopedic, Inc. | Method of treating neuronal injury by administering magnesium chloride and PEG |
US8945623B2 (en) * | 2006-05-03 | 2015-02-03 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
US9675696B2 (en) * | 2006-11-14 | 2017-06-13 | Warsaw Orthopedic, Inc. | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain |
TWI445544B (en) | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | Compositions and methods for increasing vascularization |
US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
US20090263507A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use |
BRPI0919919A2 (en) | 2008-10-21 | 2017-05-30 | Massachusetts Gen Hospital | cell transplant |
US8858924B2 (en) | 2009-03-26 | 2014-10-14 | Warsaw Orthopedic, Inc. | Compositions and methods for treatment of hemorrhage |
CA2756924A1 (en) | 2009-03-26 | 2010-09-30 | Warsaw Orthopedic, Inc. | Methods of identifying potential components for targeted drug delivery compositions |
US9244060B2 (en) | 2009-03-26 | 2016-01-26 | Warsaw Orthopedic, Inc. | Site localization and methods for monitoring treatment of disturbed blood vessels |
US8852566B2 (en) | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
US9078808B2 (en) * | 2009-03-26 | 2015-07-14 | Warsaw Orthopedic, Inc. | Device to deliver magnesium in PEG formulation |
US8606371B2 (en) | 2009-04-07 | 2013-12-10 | Dignity Health | Uterine electrical stimulation system and method |
US20110230785A1 (en) * | 2010-03-16 | 2011-09-22 | ProNerve, LLC | Somatosensory Evoked Potential (SSEP) Automated Alert System |
WO2012019103A2 (en) | 2010-08-06 | 2012-02-09 | The General Hospital Corporation D/B/A | System and apparatus for cell treatment |
US9872983B2 (en) | 2010-10-27 | 2018-01-23 | Dignity Health | Uterine electrical stimulation system and method |
US8972028B2 (en) | 2010-10-27 | 2015-03-03 | Dignity Health | Uterine electrical stimulation system and method |
US9955973B2 (en) * | 2011-02-25 | 2018-05-01 | The General Hospital Corporation | Nerve coaptation apparatus |
US20150127017A1 (en) * | 2012-05-18 | 2015-05-07 | Robert E. Garfield | Electrical stimulation of the cervix |
US11439690B2 (en) * | 2013-02-07 | 2022-09-13 | The Cleveland Clinic Foundation | Methods of treating spinal cord injury |
CN106663137B (en) | 2014-04-28 | 2020-07-10 | 耶达研究及发展有限公司 | Method and apparatus for predicting reaction to food |
GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
US11633188B2 (en) | 2017-07-26 | 2023-04-25 | Neuraptive Therapeutics, Inc. | Device and method of creating a fluid containment field for administering therapeutics to a nerve |
US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
IL291578B2 (en) * | 2019-09-27 | 2023-03-01 | Univ Virginia Commonwealth | Compositions and methods for restoring or increasing tissue perfusion |
US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
EP4093484A4 (en) * | 2020-01-21 | 2023-11-01 | The Penn State Research Foundation | Methods and materials for treating nerve injury and/or promoting wound healing |
JP2023532915A (en) * | 2020-07-09 | 2023-08-01 | ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント | Methods for protecting cells from injury |
US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369769A (en) * | 1980-06-13 | 1983-01-25 | Edwards Charles C | Spinal fixation device and method |
US4599354A (en) * | 1985-03-11 | 1986-07-08 | Morton Shulman | Composition and method for producing prolonged pain relief |
WO1992011864A1 (en) * | 1991-01-11 | 1992-07-23 | Cryopharm Corporation | Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material |
US6858409B1 (en) * | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
US4919140A (en) | 1988-10-14 | 1990-04-24 | Purdue Research Foundation | Method and apparatus for regenerating nerves |
IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
NL9000634A (en) * | 1990-03-20 | 1991-10-16 | Catharina Ziekenhuis Stichting | WATER-BASED SUSPENSION INJECTION PREPARATION, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THIS PREPARATION FOR PAIN RELIEF. |
HUT67762A (en) * | 1991-03-19 | 1995-04-28 | Cytrx Corp | Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof |
US5470568A (en) | 1992-02-13 | 1995-11-28 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for cell repair |
US5324322A (en) * | 1992-04-20 | 1994-06-28 | Case Western Reserve University | Thin film implantable electrode and method of manufacture |
US5605687A (en) * | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
CA2101311A1 (en) * | 1992-07-31 | 1994-02-01 | Neelakantan Balasubramanian | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles |
CA2085785C (en) | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
DE69614050T2 (en) * | 1995-02-14 | 2002-03-21 | Toray Industries | FLAT PRESSURE PLATE |
JPH09315972A (en) | 1996-03-22 | 1997-12-09 | Chugai Pharmaceut Co Ltd | Therapeutic drug for damaged spinal code |
US6495532B1 (en) * | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
AU751876B2 (en) | 1997-03-19 | 2002-08-29 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
US7582680B1 (en) * | 1998-11-12 | 2009-09-01 | Purdue Research Foundation | Methods and compositions for treating mammalian spinal cord injuries |
US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US6432434B1 (en) * | 1999-04-22 | 2002-08-13 | The United States Of America As Represented By The Secretary Of The Army | Treatment of and/or prophylaxis against brain and spinal cord injury |
CA2445612C (en) * | 2001-04-24 | 2011-10-25 | Purdue Research Foundation | Methods and compositions for treating mammalian nerve tissue injuries |
JP2006517807A (en) | 2002-12-30 | 2006-08-03 | パーデュー・リサーチ・ファウンデーション | Treatment of central nervous system damage |
-
2002
- 2002-04-24 CA CA2445612A patent/CA2445612C/en not_active Expired - Fee Related
- 2002-04-24 WO PCT/US2002/013375 patent/WO2002092107A1/en active Application Filing
- 2002-04-24 AT AT02741682T patent/ATE546146T1/en active
- 2002-04-24 US US10/132,542 patent/US7837987B2/en not_active Expired - Fee Related
- 2002-04-24 ES ES02741682T patent/ES2382899T3/en not_active Expired - Lifetime
- 2002-04-24 JP JP2002589024A patent/JP2004527573A/en active Pending
- 2002-04-24 NZ NZ529526A patent/NZ529526A/en not_active IP Right Cessation
- 2002-04-24 AU AU2002314758A patent/AU2002314758B2/en not_active Ceased
- 2002-04-24 NZ NZ543953A patent/NZ543953A/en not_active IP Right Cessation
- 2002-04-24 EP EP02741682A patent/EP1389121B1/en not_active Expired - Lifetime
- 2002-04-24 CA CA2740056A patent/CA2740056A1/en not_active Abandoned
-
2004
- 2004-07-28 US US10/901,481 patent/US9687502B2/en active Active
-
2006
- 2006-03-01 AU AU2006200866A patent/AU2006200866B2/en not_active Ceased
-
2009
- 2009-02-23 JP JP2009039488A patent/JP2009112835A/en active Pending
- 2009-07-23 US US12/508,184 patent/US8460646B2/en not_active Expired - Lifetime
-
2013
- 2013-06-07 US US13/912,499 patent/US9101655B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1389121B1 (en) | 2012-02-22 |
US9687502B2 (en) | 2017-06-27 |
JP2009112835A (en) | 2009-05-28 |
JP2004527573A (en) | 2004-09-09 |
US20050069520A1 (en) | 2005-03-31 |
NZ529526A (en) | 2006-06-30 |
US8460646B2 (en) | 2013-06-11 |
US9101655B2 (en) | 2015-08-11 |
US7837987B2 (en) | 2010-11-23 |
WO2002092107A1 (en) | 2002-11-21 |
US20100016444A1 (en) | 2010-01-21 |
CA2740056A1 (en) | 2002-11-21 |
US20140100289A1 (en) | 2014-04-10 |
EP1389121A1 (en) | 2004-02-18 |
AU2006200866A1 (en) | 2006-03-23 |
CA2445612C (en) | 2011-10-25 |
NZ543953A (en) | 2007-04-27 |
EP1389121A4 (en) | 2006-11-02 |
ES2382899T3 (en) | 2012-06-14 |
US20030118545A1 (en) | 2003-06-26 |
AU2002314758B2 (en) | 2006-06-01 |
AU2006200866B2 (en) | 2007-11-08 |
ATE546146T1 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2445612A1 (en) | Methods and compositions for treating mammalian nerve tissue injuries | |
JP2004527573A5 (en) | ||
JP5242415B2 (en) | Pharmacological composition with high stability | |
CA2657911C (en) | Pharmaceutical compositions for sustained release delivery of peptides | |
JP3220331B2 (en) | Absorbable liquid copolymers for parenteral administration | |
US20080152668A1 (en) | Thymosin Alpha 1 Peptide/Polymer Conjugates | |
US20090258079A1 (en) | Biocompatible Block Copolymer, Use Thereof and Manufacturing Method Thereof | |
JP2004525712A (en) | Method and apparatus for delivery of high molecular weight substances | |
WO1999053943A3 (en) | Therapeutic angiogenic factors and methods for their use | |
EP3478300B1 (en) | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells | |
WO2012150265A1 (en) | Fiber comprising a biodegradable polymer | |
AU2002353964A1 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
WO2002072019A2 (en) | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases | |
US20100204124A1 (en) | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members | |
WO2004048971A1 (en) | Methods of protecting against radiation damage using alpha thymosin | |
Patel et al. | A review: Parenteral depot drug delivery system | |
CN111511385B (en) | Pharmaceutical composition with selected duration of release | |
EP3624815A1 (en) | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells | |
Semmler et al. | 67. Silk-silk Conduits Filled with Native Spider Silk Fibers Successfully Promoted Nerve Regeneration in a 10 Mm Sciatic Nerve Defect in Rats | |
KR20220151995A (en) | Liraglutide-loaded Microneedle formulation | |
CN116831975A (en) | Microneedle patch for inducing immune tolerance to treat rheumatoid arthritis | |
GB2346329A (en) | Injection device | |
AU6177499A (en) | Pharmaceutical composition containing stimulators of interferon-gamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160425 |